CN112263600B - Carpesium abrotanoides extract, preparation method and application thereof in anti-liver cancer active drugs passing through JAK2/STAT3 channel - Google Patents
Carpesium abrotanoides extract, preparation method and application thereof in anti-liver cancer active drugs passing through JAK2/STAT3 channel Download PDFInfo
- Publication number
- CN112263600B CN112263600B CN202011163501.3A CN202011163501A CN112263600B CN 112263600 B CN112263600 B CN 112263600B CN 202011163501 A CN202011163501 A CN 202011163501A CN 112263600 B CN112263600 B CN 112263600B
- Authority
- CN
- China
- Prior art keywords
- compound
- extract
- jak2
- total extract
- stat3
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000253113 Carpesium abrotanoides Species 0.000 title claims abstract description 23
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 title claims abstract description 22
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 title claims abstract description 21
- 239000003814 drug Substances 0.000 title claims abstract description 19
- 102000004495 STAT3 Transcription Factor Human genes 0.000 title claims abstract description 18
- 108010017324 STAT3 Transcription Factor Proteins 0.000 title claims abstract description 18
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 201000007270 liver cancer Diseases 0.000 title claims abstract description 13
- 208000014018 liver neoplasm Diseases 0.000 title claims abstract description 13
- 229940079593 drug Drugs 0.000 title claims description 9
- 150000001875 compounds Chemical class 0.000 claims abstract description 29
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims abstract description 21
- 238000010262 high-speed countercurrent chromatography Methods 0.000 claims abstract description 14
- 238000001035 drying Methods 0.000 claims abstract description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims abstract description 8
- 241000196324 Embryophyta Species 0.000 claims abstract description 7
- 238000002156 mixing Methods 0.000 claims abstract description 4
- 239000002244 precipitate Substances 0.000 claims abstract description 4
- 238000002791 soaking Methods 0.000 claims abstract description 4
- 239000002904 solvent Substances 0.000 claims description 18
- 239000000126 substance Substances 0.000 claims description 7
- 229940125904 compound 1 Drugs 0.000 claims description 5
- HZQXXYJHLCSUGQ-UHFFFAOYSA-N ethyl acetate hexane methanol hydrate Chemical compound O.OC.CCCCCC.CCOC(C)=O HZQXXYJHLCSUGQ-UHFFFAOYSA-N 0.000 claims description 5
- SIHHLZPXQLFPMC-UHFFFAOYSA-N chloroform;methanol;hydrate Chemical compound O.OC.ClC(Cl)Cl SIHHLZPXQLFPMC-UHFFFAOYSA-N 0.000 claims description 4
- 101000878457 Macrocallista nimbosa FMRFamide Proteins 0.000 claims description 3
- 238000005070 sampling Methods 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 12
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 14
- 238000000926 separation method Methods 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 11
- 239000012071 phase Substances 0.000 description 10
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 9
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 229930009674 sesquiterpene lactone Natural products 0.000 description 7
- 150000002107 sesquiterpene lactone derivatives Chemical class 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 229930012538 Paclitaxel Natural products 0.000 description 5
- HATRDXDCPOXQJX-UHFFFAOYSA-N Thapsigargin Natural products CCCCCCCC(=O)OC1C(OC(O)C(=C/C)C)C(=C2C3OC(=O)C(C)(O)C3(O)C(CC(C)(OC(=O)C)C12)OC(=O)CCC)C HATRDXDCPOXQJX-UHFFFAOYSA-N 0.000 description 5
- 229960001592 paclitaxel Drugs 0.000 description 5
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 5
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- 238000011529 RT qPCR Methods 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 229940126214 compound 3 Drugs 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- -1 p-JAK2 Proteins 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 3
- 239000002033 PVDF binder Substances 0.000 description 3
- 229940125782 compound 2 Drugs 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 238000004393 prognosis Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 241000045459 Carex meyeriana Species 0.000 description 2
- 241000253115 Carpesium Species 0.000 description 2
- 230000005526 G1 to G0 transition Effects 0.000 description 2
- 102000042838 JAK family Human genes 0.000 description 2
- 108091082332 JAK family Proteins 0.000 description 2
- LIDPBIULZNRIJE-QHSBEEBCSA-N Telekin Chemical compound C1CCC(=C)[C@]2(O)C[C@@H]3C(=C)C(=O)O[C@@H]3C[C@]21C LIDPBIULZNRIJE-QHSBEEBCSA-N 0.000 description 2
- LIDPBIULZNRIJE-UHFFFAOYSA-N Telekin Natural products C1CCC(=C)C2(O)CC3C(=C)C(=O)OC3CC21C LIDPBIULZNRIJE-UHFFFAOYSA-N 0.000 description 2
- GSLDEZOOOSBFGP-UHFFFAOYSA-N alpha-methylene gamma-butyrolactone Chemical compound C=C1CCOC1=O GSLDEZOOOSBFGP-UHFFFAOYSA-N 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000000132 electrospray ionisation Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000005192 partition Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 229930004725 sesquiterpene Natural products 0.000 description 2
- 150000004354 sesquiterpene derivatives Chemical class 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- KGJUZQMPTQIFAB-IDMWBNCISA-N (3s,3ar,4ar,7s,8ar,9ar)-4a,7-dihydroxy-3,8a-dimethyl-5-methylidene-3,3a,4,6,7,8,9,9a-octahydrobenzo[f][1]benzofuran-2-one Chemical compound C=C([C@]1(O)C2)C[C@H](O)C[C@]1(C)C[C@@H]1[C@H]2[C@H](C)C(=O)O1 KGJUZQMPTQIFAB-IDMWBNCISA-N 0.000 description 1
- KGJUZQMPTQIFAB-UHFFFAOYSA-N 2alpha,5alpha-dihydroxy-11alpha(H)-eudesma-4(15)-en-8beta,12-olide Natural products C1C2(O)C(=C)CC(O)CC2(C)CC2C1C(C)C(=O)O2 KGJUZQMPTQIFAB-UHFFFAOYSA-N 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 238000009020 BCA Protein Assay Kit Methods 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 101100532034 Drosophila melanogaster RTase gene Proteins 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 101710112791 Tyrosine-protein kinase JAK2 Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000003916 acid precipitation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- AFYNADDZULBEJA-UHFFFAOYSA-N bicinchoninic acid Chemical compound C1=CC=CC2=NC(C=3C=C(C4=CC=CC=C4N=3)C(=O)O)=CC(C(O)=O)=C21 AFYNADDZULBEJA-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001793 charged compounds Chemical class 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- HQVFCQRVQFYGRJ-UHFFFAOYSA-N formic acid;hydrate Chemical compound O.OC=O HQVFCQRVQFYGRJ-UHFFFAOYSA-N 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- ZLSZUXNHKLRERC-UHFFFAOYSA-N hexane;methanol;hydrate Chemical compound O.OC.CCCCCC ZLSZUXNHKLRERC-UHFFFAOYSA-N 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000001269 time-of-flight mass spectrometry Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/15—Preparation or pretreatment of starting material involving mechanical treatment, e.g. chopping up, cutting or grinding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to the technical field of traditional Chinese medicines, and discloses a carpesium abrotanoides extract, a preparation method and application thereof in an anti-liver cancer active medicine through JAK2/STAT3 channels. The method comprises the following operation steps: drying and crushing whole plant of carpesium abrotanoides, soaking and extracting for 24h by using ethanol with the volume percentage concentration of 95%, extracting for three times, and mixing and drying extracting solutions to obtain a total extract; adding NaOH solution into the total extract to dissolve until the pH value is 9, stopping adding the NaOH solution, and then adjusting the pH value to 2 by using concentrated hydrochloric acid to obtain precipitate to obtain the Carpesium abrotanoides total extract; separating the total extract of radix Carpesii by high speed countercurrent chromatography to obtain three compounds respectively with structural formula C15H22O4Compound 1 of the formula C15H20O3Compound 2 of the structural formula C15H20O3Compound 3 of (1).
Description
Technical Field
The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a carpesium abrotanoides extract, a preparation method and application thereof in an anti-liver cancer active medicine through JAK2/STAT3 channels.
Background
The genus carpesium is a genus of the family asteraceae, about 21, and is mainly distributed in southern europe and asia. Wherein,there are 17 species in the southwest mountain area of China. Tianming Jing, a famous ethnic medicine, has a long medicinal history in the Tujia, Bai nationality, Miao nationality and other minority nationalities. The research shows that the sesquiterpene lactone mainly contains chemical components such as sesquiterpene lactone, and most of the sesquiterpene lactone contains alpha-methylene-gamma-butyrolactone, and has biological activities such as anticancer, anti-inflammatory and antibacterial activities. Screening of cck-8 activity at the early stage shows that the total Sesquiterpene Lactone Extract (SLEC) has good effect (IC) on HepG-2 cells504.2 mug/ml), but the effective components and the action mechanism of the medicine for resisting liver cancer are not clear.
The aim of modern Chinese medicine research is to explain which chemical components of Chinese medicine are effective and how to act. Although a complete system is formed by the traditional extraction, separation and analysis method, the defects of time consumption, labor waste, long period and the like still exist, and the traditional extraction, separation and analysis method cannot meet and adapt to the research of modern traditional Chinese medicine.
Among them, high-speed countercurrent chromatography (HSCCC) is a very effective tool for separation and purification of Chinese herbs. Compared with other separation methods, the method does not use a solid carrier as a stationary phase, but disperses a separated sample in an immiscible two-phase liquid to achieve the separation effect. Therefore, the HSCCC has the advantages of high loading capacity, high preparation efficiency, low solvent consumption, good repeatability and the like.
High performance liquid chromatography tandem quadrupole time-of-flight mass spectrometry (HPLC-Q-TOF-MS)E) Accurate information such as molecular ion peaks and fragment ions can be rapidly acquired, and then different types of chemical components can be analyzed and identified. Therefore, we used HPLC-Q-TOF-MSEThe strategy identifies the sesquiterpene component in carpesium abrotanoides, guides HSCCC to rapidly separate out compounds with large active parts, and finally uses the separated compounds for anti-liver cancer activity through a JAK2/STAT3 signal channel.
Disclosure of Invention
In order to overcome the defects in the prior art, the invention mainly aims to provide a preparation method of carpesium abrotanoides extract.
The invention also aims to provide the carpesium abrotanoides extract prepared by the preparation method.
The invention also aims to provide application of the carpesium abrotanoides extract prepared by the preparation method.
The purpose of the invention is realized by the following technical scheme:
a preparation method of carpesium abrotanoides extract comprises the following operation steps:
(1) taking whole plant of carpesium abrotanoides, drying, crushing, soaking and extracting for 24 hours by using ethanol with volume percentage concentration of 95% and mass which is 10 times of that of the whole plant of carpesium abrotanoides, extracting for three times, mixing extracting solutions of the three times, concentrating, and drying to obtain a total extract; adding NaOH solution with the mass percentage concentration of 2% into the total extract for dissolving until the pH value is 9, stopping adding the NaOH solution, and then adjusting the pH value to 2 by using concentrated hydrochloric acid with the mass percentage concentration of 1% to obtain a precipitate to obtain the carpesium abrotanoides total extract;
(2) separating the total extract of radix Carpesii by high speed countercurrent chromatography to obtain three compounds respectively with structural formula C15H22O4Compound 1 of the formula C15H20O3Compound 2 of the structural formula C15H20O3Compound 3 of (1);
the parameters of the high-speed counter-current chromatography are as follows: firstly, when an n-hexane-ethyl acetate-methanol-water solvent system with the flow rate of 3.0mL/min, the rotation speed of 835rpm, the sampling amount of 200mg and the volume ratio of 1:9:9:1 is adopted to run for 150min, the pump stops working; then replacing the solvent system with chloroform-methanol-water in a volume ratio of 4:3: 2; after operating for 320min, the pump is closed, so that a peak A is obtained in 60-66min of the first stage, a peak B is obtained in 74-82min, and a peak C is obtained in 80-92min of the second stage, wherein the peak A corresponds to a compound 1, a compound 2 and a compound 3 respectively;
a Carpesium total extract prepared by the above preparation method is provided.
The application of the total extract of carpesium abrotanoides in preparing anti-liver cancer active medicines through JAK2/STAT3 channels.
The compound 1 is applied to the anti-liver cancer active drugs through JAK2/STAT3 channels.
The application of the compound 2 in the anti-liver cancer active drug through JAK2/STAT3 channels.
The application of the compound 3 in anti-liver cancer active drugs through JAK2/STAT3 channels.
Compared with the prior art, the invention has the following advantages and effects:
(1) the invention adopts the method of alkali dissolution and acid precipitation to extract the total sesquiterpene component of carpesium abrotanoides for the first time;
(2) the invention adopts high-speed counter-current chromatography to separate the three active substances with the highest content in the carpesium abrotanoides extract, thereby overcoming the defects of time consumption and labor waste of the carpesium abrotanoides extraction process in the prior art;
(3) the carpesium abrotanoides extract extracted by the invention has very obvious anti-liver cancer activity through JAK2/STAT3 channels.
Drawings
FIG. 1 is a positive, negative TIC and UV map of SLEC sites.
Fig. 2 and 3 are chromatograms of compounds prepared by HSCCC.
FIG. 4 is a graph of the effect of compounds 1-3 on JAK2 and STAT3mRNA expression in HepG2 cells.
FIG. 5 is a graph showing the effect of compounds 1-3 on JAK2, p-JAK2, STAT3, and p-STAT3 protein expression in HepG2 cells.
Detailed Description
The following further describes the present invention with reference to specific examples and drawings, but the present invention should not be construed as being limited thereto. Unless otherwise specified, the technical means used in the examples are conventional means well known to those skilled in the art. Reagents, methods and apparatus used in the present invention are conventional in the art unless otherwise indicated.
Example 1:
first, the method used in this embodiment:
1. preparation of carpesium abrotanoides extract
Taking 2Kg of Carex meyeriana whole plant, drying and crushing, soaking for 24h with 95% ethanol with the volume percentage concentration of 10 times of the Carex meyeriana whole plant, extracting for three times, mixing the three extracting solutions, and drying to obtain 458g of Total Extract (TEC). TEC (400g) was dissolved in 2% by weight NaOH solution until pH 9, and then concentrated 1% by weight hydrochloric acid was used to adjust pH to 2 to obtain a precipitate, and total sesquiterpene lactone total extract (SLEC) (42g) was obtained.
2. Screening of antitumor Activity by cck-8 method
Cells in logarithmic growth phase were taken, counted by digestion, and counted at3 x 103The cells were seeded at a density of 100. mu.L per well in 96-well plates. Each group is provided with 3 multiple wells, after adherence culture, TEC parts, SLEC parts and residual samples with different concentrations (50, 100, 150, 200 and 250g/mL) are respectively subjected to medicine adding treatment for corresponding time, according to each well, 10 mu l/well of cck8 is added, complete culture medium is used for preparing cck8 solution (100 ul of cck8 solution is added according to 1mL of complete culture medium), and 100ul of culture medium containing cck8 is added into each well of the medicine-containing culture medium. 37 ℃ and 5% CO2After further incubation for 4 hours, absorbance (OD) values at 450nm were analyzed on a Bio-Tek microplate reader.
3. Liquid mass analysis of active site
By HPLC-Q-TOF-MSEThe chemical composition of the SLEC site was analyzed. The liquid phase condition is Agilent high performance liquid chromatography column (Eclipse XDB C)184.6X 250X 5 μm); mobile phase a was 0.1% formic acid water, mobile phase B was acetonitrile, elution procedure: 0-8min, 2% B; 8-10min, 2% -20% B; 10-50min, 20% -52% B; 50-60min, 52% B; 60-65min, 52% -80% B; 65-68min, 80-98% B; 68-75min, 98% B column temperature 25 deg.C, volume flow 1.0mL/min, injection volume 5 μ L.
The mass spectrum conditions are as follows: mass spectrum condition ionization mode electrospray ionization (ESI), collecting positive and negative ion modes respectively, wherein the temperature of the drying gas is 325 ℃, the volume flow of the drying gas is 6.8 L.min < -1 >, the temperature of the sheath gas is 350 ℃, the voltage of a capillary tube is 4.0kV, the fragment voltage is 130V, and the mass number range is m/z 50-1000.
4. Preparation method of HSCCC
4.1 determination of partition coefficient
The distribution coefficients of the SLEC sites in different solvent systems were calculated by HPLC in this experiment. The specific operation is as follows: preparing a certain volume (20mL) of upper and lower phase solvents according to a solvent system proportion, placing the upper and lower phase solvents with the same volume in the same container (10mL test tube) after phase separation balance, adding a certain amount (0.1g) of sample, shaking violently to dissolve, and standing. And (3) taking upper and lower phase solvents with the same volume, injecting HPLC (high performance liquid chromatography) to measure peak areas AS and AM of the target component in the upper and lower phases, and calculating a distribution coefficient K value according to AS/AM.
4.2HSCCC separation
The solvent system is selected primarily based on the partition coefficient of the target. Five solvent systems: n-hexane-ethyl acetate-methanol-water (1:1:1:1), n-hexane-ethyl acetate-methanol-water (1:9:9:1), n-hexane-ethyl acetate-methanol-water (3:1:1:1), n-hexane-methanol-water (5:4:1), and chloroform-methanol-water (4:3:2) were used to perform SLEC site separation experiments, respectively.
For each separation experiment, the separation column was packed with 30.0mL/min of stationary phase, followed by forward rotation (FWD) at 835 rpm. The mobile phase was pumped into the instrument at a rate of 3.0 mL/min. After equilibrium is reached, the sample is injected into the injection valve. Monitoring was continued at 218nm, with a UV detector to monitor the peak composition.
5. In vitro cell experiments
The cytotoxicity of the isolated compound (1-3) against HegG-2 cell line was examined by the cck-8 method.
5.1 quantitative real-time polymerase chain reaction
Total RNA was extracted from HepG-2 cells using TRIzol reagent. Approximately 500ng of total RNA was reverse transcribed per sample using PrimeScript II RTase reverse transcriptase to prepare cDNA. Quantitative real-time polymerase chain reaction (qRT-PCR) was performed using CFX-Connect 96 and SYBR fast qPCR master batches. The PCR primer sequence is JAK2, forward ACTAAATGCTGTCCCCC, reverse TTCATGCAGTTGACCGT; STAT3, forward TGAGGGAGCAGAGATGTG, reverse TGGGGGCTTGGTAAAA; GAPDH, forward CCACTCCTCCACCTTTG, reverse CACCACCCTGTTGCTGT. Relative GAPDH expression calculation for each target Gene 2 was used-ΔΔCA method.
5.2 immunoblot detection
Total protein was extracted from RA-FLS using RIPA lysis buffer and protein concentration was measured using BCA protein assay kit. After the 20mg sample is completely lysed with 200mol/L lysis buffer, the sample is centrifuged at 1200rpm for 20min at 4 ℃, and the supernatant is taken for western blot analysis. The protein concentration of each sample was determined from Bicinchoninic Acid protein Assay kit. The loaded proteins were electrophoresed and separated on a 10% SDS-polyacrylamide gel (SDS-PAGE), and then transferred onto a polyvinylidene fluoride (PVDF) membrane. PVDF membranes were blocked in 5% skim milk for 1 hour at room temperature and incubated with primary antibodies (JAK2, Anti-JAK2, STAT3, Anti-STAT3, GAPDH) overnight at 4 ℃. The membrane was washed 4 times 5 minutes each with PBST. Adding goat anti-rabbit IgG (1:10000), incubating at room temperature for 1h, detecting by ECL, and reading the gray value of the related strip by TANON GIS software.
6. Statistical analysis
The comparisons between groups were expressed as Standard Deviations (SD) using one-way analysis of variance (ANOVA) and t-test. All statistical analyses were significant at p <0.05 or p <0.01 using SPSS 15.0.
Second, experimental conclusion
1. ccK-8 method for treating TEC and SLEC with anti-tumor effect
The CCk8 method was used to evaluate the cytotoxicity of TEC and SLEC sites on tumor cell lines Hela, HepG2, SW620, A549, HL-60, smmc-7721 and PC-3. The results are shown in Table 1. From the table, it can be seen that TEC and SLEC both have some effect on different types of tumor cells. In particular, SLEC sites showed good activity against HepG-2 and Smmc-7721 cells.
Table 1: IC of parts of radix Carpesii on cancer cells50Value of
2. Liquid mass analysis
Based on the fact that SLEC parts have good activity on hepatoma cells, the chemical components of SLEC parts are analyzed by HPLC-Q-TOF-MS/MS. Mass spectrometry was performed in positive and negative modes, respectively, by optimization of liquid phase and mass spectrometry conditions, as shown in figure 1 and table 2. It was found that this type of compound (sesquiterpene lactones) has a higher response in the positive mode, mainly with [ M + H ]]+Exists in the form of (1), further researchIon peaks and the cracking law of multi-stage mass spectrometry, a large number of isomers are found. Therefore, the specific compound name needs to be further determined by other methods.
Table 2: chemical composition study of SLEC sites
3. HSCCC fast separation
The selection of a suitable biphasic solvent system is critical to the high performance separation of HSCCC, and typically requires high performance liquid chromatography to detect the appropriate k-value of the target component. In general, the value of K should be between 0.5 and 2.0.
The k values for the three target compounds by HPLC analysis are shown in Table 3. As can be seen from the table, the A and B peaks are well suited for solvent system 2. However, peak C is not suitable for this and is suitable for solvent system 5. Thus, when the mobile phase was running for 150min, the pump was stopped and the solvent system was then replaced with chloroform-methanol-water (v/v/v,4:3: 2). After 320min, the A peak (60-66min), the B peak (74-82min) and the C peak (80-92min) are obtained, as shown in FIG. 3.
Table 3: HSCCC separation of SLEC Compounds in different solvent systems
Besides a solvent system, factors such as the flow speed and the rotating speed of a mobile phase, the sample loading amount and the like are considered in an experiment. Different flow rates (1.5, 2.0, 2.5 and 3.0mL/min), different rotational speeds (700, 800, 835 and 850rpm) and sample loadings (50, 100, 150 and 200mg) were compared. The results show that good separation efficiency can be obtained when the flow rate is 3.0mL/min, the rotation speed is 835rpm, and the sampling amount is 200 mg. The chromatograms are shown in FIGS. 2 and 3.
4. Structural identification of isolated sesquiterpene lactones
The obtained compounds are all prepared by HPLC-Q-TOF-MS,1H-NMR、13C-NMR was identified and compared with relevant literature. Their detailed data are shown below, and it was confirmed that they are each of the structural formula C15H22O4The compound 1(2 alpha, 5 alpha-dihydroxy-11 alpha H-eudesma-4(15) -en-12,8 beta-olide) has a structural formula of C15H20O3Compound 2 (Telekin) with structural formula C15H20O3Compound 3(1-oxoeudesm-11(13) -eno-12,8 a-lactone):
2α,5α-dihydroxy-11αH-eudesma-4(15)-en-12,8β-olide(A):ESI-MS,m/z267.1541[M+H]+,C15H22O4.1H NMR(600MHz,MeOD)δ:0.89(s,3H,H-14),1.17(d,J＝7.2Hz,3H,H-13),1.41(td,J＝6.2,5.5,1.9Hz,1H,H-1β),1.43(m,1H,H-6β),1.69(dd,J＝13.8,6.1Hz,1H,H-6α),1.80(m,1H,H-1α),1.83(m,1H,H-9β),2.03(dd,J＝15.4,4.7Hz,1H,H-9α),2.40(ddd,J＝12.2,5.4,1.9Hz,1H,H-3β),2.61(m,1H,H-3α),2.83(dtd,J＝12.7,6.4,4.3Hz,1H,H-7),2.97(p,J＝7.1Hz,1H,H-11),3.80(tt,J＝11.3,5.1Hz,1H,H-2),4.59(td,J＝4.5,1.7Hz,1H,H-8),4.80(t,J＝1.5Hz,1H,H-15),4.94(t,J＝1.5Hz,1H,H-15).13C NMR(151MHz,MeOD)δ:180.8(C-12),149.7(C-4),108.8(C-15),78.5(C-8),72.1(C-5),66.1(C-2),43.7(C-1),40.9(C-3),40.7(C-11),37.1(C-7),36.5(C-10),35.4(C-9),26.6(C-6),21.5(C-14),8.2(C-13).
Telekin(B):ESI-MS,m/z 249.1418[M+H]+,C15H20O3.1H NMR(600MHz,CDCl3)δ:0.98(s,3H,H-14),3.37(m,1H,H-7),4.58(td,J＝5.2,1.5Hz,1H,H-8),4.71(t,1H,H-15),4.88(t,1H,H-15),5.61(d,1H,J＝1.1Hz,H-13),6.16(d,1H,J＝1.2Hz,H-13).13C NMR(151MHz,CDCl3)δ:170.8(C-12),150.1(C-4),142.1(C-11),120.3(C-13),109.0(C-15),77.0(C-8),74.3(C-5),37.6(C-7),36.5(C-10),35.6(C-1),35.4(C-2),33.8(C-3),31.8(C-9),21.8(C-14),21.6(C-6).
1-oxoeudesm-11(13)-eno-12,8a-lactone(C):ESI-MS,m/z 249.1423[M+H]+,C15H20O3.1H NMR(600MHz,CDCl3)δ:0.96(s,3H,H-14),1.02(d,J＝5.8Hz,3H,H-15),1.35(q,J＝11.9Hz,1H,H-9),1.45(dd,J＝14.8,11.8Hz,1H,H-6),1.55(m,1H,H-2),1.83(m,1H,H-5),1.87(m,1H,H-4),2.04(m,1H,H-6),2.10(m,1H,H-2),2.43(m,1H,H-3),2.39(dd,J＝9.4,4.2Hz,1H,H-9),2.70(m,1H,H-7),4.21(ddd,J＝12.0,9.2,3.1Hz,1H,H-8),5.44(d,J＝3.2Hz,1H,H-13),6.11(d,J＝3.5Hz,1H,H-13).13C NMR(151MHz,CDCl3)δ:222.0(C-1),169.8(C-12),140.2(C-11),120.1(C-13),80.8(C-8),50.0(C-10),48.7(C-5),44.8(C-7),44.1(C-3),35.2(C-2),34.5(C-9),29.6(C-4),24.1(C-6),22.0(C-14),20.0(C-15).
5. activity verification
Experiments show that the SLEC part has obvious inhibition effect on HepG-2 cells. Thus, this experiment was continued with in vitro cell experimental validation of the three isolated compounds. The results show that all three compounds show some inhibitory effect (IC50 ═ 9.83, 2.95, 4.15 μ M).
5.1 Effect of Compounds on HepG-2 cell JAK2 and STAT3mRNA expression
As shown in FIG. 4, the mRNA expression levels of both JAK-2 and STAT-3 were significantly reduced for the positive control paclitaxel compared to the control group (p < 0.01). Given compound-dried prognosis, high and intermediate concentrations of JAK-2mRNA expression levels of compounds 1 and 2 were significantly reduced compared to the control group (p < 0.01); the JAK-2mRNA expression level of the compound 3 is obviously reduced compared with that of a control group (p <0.05), and the compound has concentration dependence; STAT-3mRNA expression levels were reduced (p <0.01) for compounds 1, 2 and 3 compared to the control group and were concentration dependent.
5.2 Effect of Compounds on HepG-2 cell JAK2 and STAT3mRNA expression
As shown in figure 4, mRNA expression levels of both JAK2 and STAT3 were significantly reduced for the positive control paclitaxel compared to the control group (p < 0.01). Given compound-dried prognosis, high and intermediate concentrations of JAK 2mRNA expression levels of compounds 1 and 2 were significantly reduced compared to the control group (p < 0.01); JAK 2mRNA expression levels of compound 3 were significantly reduced (p <0.05) compared to the control group and were concentration dependent; STAT3mRNA expression levels were reduced (p <0.01) for compounds 1, 2, and 3 compared to the control group and were concentration dependent.
5.3 Effect of Compounds on the expression of JAK2, p-JAK2, STAT3, p-STAT3 proteins from HepG2 cells
As shown in FIG. 5, the p-JAK2 and p-STAT3 protein expression levels of the positive control paclitaxel were significantly reduced (p <0.01) compared to the control group. Given the compound-dried prognosis, the high and medium concentrations of p-JAK2 and p-STAT3 protein expression levels of compounds 1 and 3 were significantly reduced compared to the control group (p <0.05 or p < 0.01); the expression level of p-JAK2 protein at high concentration of compound 2 was significantly reduced (p <0.05), and the expression level of p-STAT3 protein at high and medium concentration of compounds 1 and 3 was significantly reduced (p <0.05 or p < 0.01). This suggests that compounds 1, 2, 3 and the positive drug paclitaxel can significantly inhibit the expression of p-JAK2 and p-STAT3 proteins. Paclitaxel, JAK2 of compounds 1-3, and STAT3 protein expression were not statistically significant on average.
The above embodiments are preferred embodiments of the present invention, but the present invention is not limited to the above embodiments, and any other changes, modifications, substitutions, combinations, and simplifications which do not depart from the spirit and principle of the present invention should be construed as equivalents thereof, and all such changes, modifications, substitutions, combinations, and simplifications are intended to be included in the scope of the present invention.
Sequence listing
<110> Hunan province institute of traditional Chinese medicine
<120> an radix Carpesii extract, a preparation method and application thereof in anti-liver cancer active drugs through JAK2/STAT3 channels
<130> 1
<160> 6
<170> SIPOSequenceListing 1.0
<210> 1
<211> 17
<212> DNA
<213> Artificial
<220>
Claims (1)
1. The application of the compound 1 as a unique active ingredient in preparing anti-liver cancer active drugs through JAK2/STAT3 channels is characterized in that: the chemical name of the compound 1 is 2 alpha, 5 alpha-dihydroxy-11 alpha H-eudesma-4(15) -en-12,8 beta-olide, and the compound is prepared according to the following preparation method:
(1) taking whole plant of carpesium abrotanoides, drying, crushing, soaking and extracting for 24 hours by using ethanol with volume percentage concentration of 95% and mass which is 10 times of that of the whole plant of carpesium abrotanoides, extracting for three times, mixing extracting solutions of the three times, concentrating, and drying to obtain a total extract; adding NaOH solution with the mass percent concentration of 2% into the total extract for dissolving until the pH is =9, stopping adding the NaOH solution, and then adjusting the pH to 2 by using concentrated hydrochloric acid with the mass percent concentration of 1% to obtain a precipitate to obtain the carpesium abrotanoides total extract;
(2) separating the total extract of radix Carpesii by high speed countercurrent chromatography to obtain three compounds respectively with structural formula C15H22O4Compound 1 of the formula C15H20O3Compound 2 of the structural formula C15H20O3Compound 3 of (1);
the parameters of the high-speed counter-current chromatography are as follows: firstly, when an n-hexane-ethyl acetate-methanol-water solvent system with the flow rate of 3.0mL/min, the rotation speed of 835rpm, the sampling amount of 200mg and the volume ratio of 1:9:9:1 is adopted to run for 150min, the pump stops working; then replacing the solvent system with chloroform-methanol-water in a volume ratio of 4:3: 2; after 320min of operation, the pump was turned off, resulting in peak a at 60-66min in the first stage, peak B at 74-82min, and peak C at 80-92min in the second stage, peak a corresponding to compound 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011163501.3A CN112263600B (en) | 2020-10-27 | 2020-10-27 | Carpesium abrotanoides extract, preparation method and application thereof in anti-liver cancer active drugs passing through JAK2/STAT3 channel |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011163501.3A CN112263600B (en) | 2020-10-27 | 2020-10-27 | Carpesium abrotanoides extract, preparation method and application thereof in anti-liver cancer active drugs passing through JAK2/STAT3 channel |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112263600A CN112263600A (en) | 2021-01-26 |
| CN112263600B true CN112263600B (en) | 2022-07-05 |
Family
ID=74342256
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011163501.3A Active CN112263600B (en) | 2020-10-27 | 2020-10-27 | Carpesium abrotanoides extract, preparation method and application thereof in anti-liver cancer active drugs passing through JAK2/STAT3 channel |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112263600B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1566942A (en) * | 2003-06-26 | 2005-01-19 | 中国科学院过程工程研究所 | Method for drafting traditional Chinese medicinal spectrum by employing high-speed reverse-flow chromatogram |
| CN101773532A (en) * | 2010-02-24 | 2010-07-14 | 周小江 | Carpesium abrotanoides total terpene lactones extract |
| CN103788037A (en) * | 2012-11-02 | 2014-05-14 | 西北农林科技大学 | Method for purifying carabrone |
-
2020
- 2020-10-27 CN CN202011163501.3A patent/CN112263600B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1566942A (en) * | 2003-06-26 | 2005-01-19 | 中国科学院过程工程研究所 | Method for drafting traditional Chinese medicinal spectrum by employing high-speed reverse-flow chromatogram |
| CN101773532A (en) * | 2010-02-24 | 2010-07-14 | 周小江 | Carpesium abrotanoides total terpene lactones extract |
| CN103788037A (en) * | 2012-11-02 | 2014-05-14 | 西北农林科技大学 | Method for purifying carabrone |
Non-Patent Citations (4)
| Title |
|---|
| A natural compound derivative P-13 inhibits STAT3 signaling by covalently inhibiting Janus kinase 2;Huang,Hui等;《Investigational New Drugs》;20180803;第37卷(第3期);第452-460页 * |
| Telekin induces apoptosis associated with the mitochondria-mediated pathway in human hepatocellular carcinoma cells;Zheng,Beibei等;《Biological & Pharmaceutical Bulletin》;20130509;第36卷(第7期);第1118-1125页 * |
| 天名精属植物的倍半萜类成分及其药理活性研究进展;陈迪路等;《中国中药杂志》;20200101;第45卷(第01期);第37-51页 * |
| 天名精萜类化学成分及其细胞毒活性研究;汪蕾等;《中草药》;20180212;第49卷(第03期);第530-535页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112263600A (en) | 2021-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Csupor et al. | Recent advances in the analysis of flavonolignans of Silybum marianum | |
| Flamini | Recent applications of mass spectrometry in the study of grape and wine polyphenols | |
| Wang et al. | Identification of prenyl flavonoid glycosides and phenolic acids in Epimedium koreanum Nakai by Q-TOF-MS combined with selective enrichment on “click oligo (ethylene glycol)” column | |
| MacDonald | Biosynthesis of pulcherriminic acid | |
| Li et al. | Development of a method to screen and isolate potential α‐glucosidase inhibitors from Panax japonicus CA Meyer by ultrafiltration, liquid chromatography, and counter‐current chromatography | |
| CN110483599B (en) | Method for separating flavonoid components from sweetsop leaves | |
| Liu et al. | Simultaneous determination of icariin, icariside II and osthole in rat plasma after oral administration of the extract of Gushudan (a Chinese compound formulation) by LC–MS/MS | |
| Deng et al. | Qualitative and quantitative analysis of flavonoids in the leaves of Isatis indigatica Fort. by ultra-performance liquid chromatography with PDA and electrospray ionization tandem mass spectrometry detection | |
| Han et al. | Quick identification of apoptosis inducer from Isodon eriocalyx by a drug discovery platform composed of analytical high-speed counter-current chromatography and the fluorescence-based caspase-3 biosensor detection | |
| Luo et al. | Monofloral triadica cochinchinensis honey polyphenols improve alcohol-induced liver disease by regulating the gut microbiota of mice | |
| Wu et al. | Simultaneous screening and isolation of activated constituents from Puerariae Flos by ultrafiltration with liquid chromatography and mass spectrometry combined with high‐speed counter‐current chromatography | |
| CN115015428A (en) | Detection method of polyphenol compounds in yellow wine | |
| Du et al. | The metabolic profiling of isorhamnetin-3-O-neohesperidoside produced by human intestinal flora employing UPLC-Q-TOF/MS | |
| CN105669631B (en) | A kind of potentilla plants extract and the method for therefrom separating four kinds of tanninses compounds | |
| Wang et al. | Characterization of interaction property of multi‐components in Gardenia jasminoides with aldose reductase by microdialysis combined with liquid chromatography coupled to mass spectrometry | |
| Sun et al. | Qualitative and quantitative analysis of furofuran lignans, iridoid glycosides, and phenolic acids in Radix Dipsaci by UHPLC-Q-TOF/MS and UHPLC-PDA | |
| CN104262445A (en) | Camellia nitidissima saponin A, and preparation method and antitumor application thereof | |
| Huang et al. | Characterization and identification of saikosaponins in crude extracts from three Bupleurum species using LC‐ESI‐MS | |
| CN112263600B (en) | Carpesium abrotanoides extract, preparation method and application thereof in anti-liver cancer active drugs passing through JAK2/STAT3 channel | |
| Wang et al. | Online extraction and enrichment coupling with high‐speed counter‐current chromatography for effective and target isolation of antitumor anthraquinones from seeds of Cassia obtusifolia | |
| CN115960029B (en) | Alkaloid in pseudo-tricholoma matsutake as well as extraction and separation method and application thereof | |
| Rong-Rong et al. | Rapid screening and identification of sesquiterpene lactones in Kudiezi injection based on high-performance liquid chromatography coupled with linear ion trap-orbitrap mass spectrometry | |
| Luan et al. | Determination of Raddeanin A in rat plasma by liquid chromatography–tandem mass spectrometry: Application to a pharmacokinetic study | |
| Shen et al. | Sesquiterpene lactones isolated from Carpesium abrotanoides L. by LC–MS combined with HSCCC inhibit liver cancer through suppression of the JAK2/STAT3 signaling pathway | |
| CN107163009B (en) | The miscellaneous terpene compound of ganoderma lucidum, its Pharmaceutical composition and its application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |